Bristol Myers Squibb’s Zeposia boosts remission rates over placebo in ulcerative colitis patients
As one of the hottest markets in pharmaceuticals, immunology has become a murderers’ row of blockbuster drugs in recent years. But Bristol Myers Squibb has big hopes for a next-gen entry in Zeposia, and it’s angling for a foothold in ulcerative colitis to get the ball rolling. Zeposia helped 18.4% of ulcerative colitis patients reach clinical remission at… Read More »
